Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Instituto do Cancer do Estado de São Paulo
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Alliance for Clinical Trials in Oncology
AstraZeneca
Sotio Biotech Inc.
M.D. Anderson Cancer Center
Kaiser Permanente
Institut du Cancer de Montpellier - Val d'Aurelle
Jonsson Comprehensive Cancer Center
University of Colorado, Denver
Hospices Civils de Lyon
xCures
University of Nebraska
Adela, Inc
RenJi Hospital
Degron Therapeutics Co.
National Cancer Institute (NCI)
UNC Lineberger Comprehensive Cancer Center
The University of Texas Health Science Center at San Antonio
Actym Therapeutics, Inc.
M.D. Anderson Cancer Center
Washington University School of Medicine
Sensei Biotherapeutics, Inc.
Jonsson Comprehensive Cancer Center
Apollomics Inc.
ModeX Therapeutics, An OPKO Health Company
University of Alabama at Birmingham
TransThera Sciences (Nanjing), Inc.
Columbia University
Theratechnologies
SOLTI Breast Cancer Research Group
Cedars-Sinai Medical Center
Cedars-Sinai Medical Center
Algemeen Ziekenhuis Maria Middelares
National Cancer Institute (NCI)
Children's Hospitals and Clinics of Minnesota
Rutgers, The State University of New Jersey
Universidade Federal de Pernambuco
Taproot Health
University of Modena and Reggio Emilia
VitaMed Research LLC
Salubris Biotherapeutics Inc
TransThera Sciences (Nanjing), Inc.
Beijing Friendship Hospital
M.D. Anderson Cancer Center